PT1409672E - Oligonucleótideos antisense capazes de inibir a formação de capilares pelas células endoteliais - Google Patents
Oligonucleótideos antisense capazes de inibir a formação de capilares pelas células endoteliais Download PDFInfo
- Publication number
- PT1409672E PT1409672E PT02751246T PT02751246T PT1409672E PT 1409672 E PT1409672 E PT 1409672E PT 02751246 T PT02751246 T PT 02751246T PT 02751246 T PT02751246 T PT 02751246T PT 1409672 E PT1409672 E PT 1409672E
- Authority
- PT
- Portugal
- Prior art keywords
- animals
- microm
- day
- nucleic acid
- antisense
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 210000002889 endothelial cell Anatomy 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 4
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 abstract 3
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 abstract 2
- 206010029113 Neovascularisation Diseases 0.000 abstract 2
- 230000000692 anti-sense effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 229920002307 Dextran Polymers 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000003257 anti-anginal effect Effects 0.000 abstract 1
- 230000002456 anti-arthritic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 230000003356 anti-rheumatic effect Effects 0.000 abstract 1
- 239000003435 antirheumatic agent Substances 0.000 abstract 1
- 239000007975 buffered saline Substances 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003203 everyday effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 238000010186 staining Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0107805A FR2826010B1 (fr) | 2001-06-14 | 2001-06-14 | Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par les cellules endotheliales |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1409672E true PT1409672E (pt) | 2009-11-04 |
Family
ID=8864317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02751246T PT1409672E (pt) | 2001-06-14 | 2002-06-14 | Oligonucleótideos antisense capazes de inibir a formação de capilares pelas células endoteliais |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7417033B2 (https=) |
| EP (2) | EP1409672B1 (https=) |
| JP (1) | JP4153421B2 (https=) |
| AT (1) | ATE435911T1 (https=) |
| AU (1) | AU2002345669B9 (https=) |
| CA (1) | CA2451874C (https=) |
| CY (1) | CY1109464T1 (https=) |
| DE (1) | DE60232883D1 (https=) |
| DK (1) | DK1409672T3 (https=) |
| ES (1) | ES2331835T3 (https=) |
| FR (1) | FR2826010B1 (https=) |
| PT (1) | PT1409672E (https=) |
| WO (1) | WO2002103014A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1931993A2 (en) * | 2005-09-14 | 2008-06-18 | Medizinische Universität Wien | Means and methods for diagnosing endometriosis |
| US8032556B1 (en) * | 2008-03-07 | 2011-10-04 | Symantec Corporation | Systems and methods for user profile data delivery |
| US8580947B2 (en) | 2009-02-05 | 2013-11-12 | Gene Signal International Sa | Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization |
| US8470997B2 (en) | 2009-02-05 | 2013-06-25 | Gene Signal International Sa | Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization |
| US20120041047A1 (en) * | 2010-08-10 | 2012-02-16 | Gene Signal International Sa | Injectable Pharmaceutical Composition for Preventing, Stabilizing and/or Inhibiting Pathological Neovascularization-Related Conditions |
| EP2540828A1 (en) | 2011-06-30 | 2013-01-02 | Gene Signal International SA | Composition comprising inhibitors of IRS-1 and of VEGF |
| US9682144B2 (en) | 2011-06-30 | 2017-06-20 | Gene Signal International, Sa | Composition comprising inhibitors of IRS-1 and of VEGF |
| WO2013001080A1 (en) | 2011-06-30 | 2013-01-03 | Gene Signal International Sa | Composition comprising inhibitors of irs-1 and of vegf |
| US9359604B2 (en) * | 2012-07-03 | 2016-06-07 | Gene Signal International Sa | Inhibitor of IRS-1 for treating skin disorders |
| US10052343B1 (en) | 2017-02-03 | 2018-08-21 | Gene Signal International Sa | Sterile formulation comprising a stable phosphorothioate oligonucleotide |
| WO2026000245A1 (zh) * | 2024-06-26 | 2026-01-02 | 思合基因(北京)生物科技有限公司 | 一种靶向IRS-1 mRNA的寡聚核苷酸及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992013083A1 (en) * | 1991-01-18 | 1992-08-06 | Joslin Diabetes Center, Inc. | Nucleic acid encoding insulin receptor substrate-1 (irs-1), irs-1 protein, diseases, therapy associated with the metabolism of irs-1 |
| FR2733913B1 (fr) * | 1995-05-09 | 1997-08-01 | Sanofi Sa | Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant |
| US6498139B1 (en) * | 1997-09-29 | 2002-12-24 | Daiichi Pharmaceutical Co., Ltd. | Remedies for diseases caused by insulin resistance |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| KR100739938B1 (ko) * | 1999-05-18 | 2007-07-16 | 가부시키가이샤 디나벡크 겐큐쇼 | 엔벨로프 유전자 결손 파라믹소과 바이러스 벡터 |
-
2001
- 2001-06-14 FR FR0107805A patent/FR2826010B1/fr not_active Expired - Fee Related
-
2002
- 2002-06-14 EP EP02751246A patent/EP1409672B1/fr not_active Expired - Lifetime
- 2002-06-14 PT PT02751246T patent/PT1409672E/pt unknown
- 2002-06-14 EP EP09164013A patent/EP2166095A3/fr not_active Withdrawn
- 2002-06-14 AU AU2002345669A patent/AU2002345669B9/en not_active Ceased
- 2002-06-14 WO PCT/FR2002/002067 patent/WO2002103014A2/fr not_active Ceased
- 2002-06-14 ES ES02751246T patent/ES2331835T3/es not_active Expired - Lifetime
- 2002-06-14 JP JP2003505336A patent/JP4153421B2/ja not_active Expired - Fee Related
- 2002-06-14 DE DE60232883T patent/DE60232883D1/de not_active Expired - Lifetime
- 2002-06-14 CA CA2451874A patent/CA2451874C/fr not_active Expired - Fee Related
- 2002-06-14 AT AT02751246T patent/ATE435911T1/de active
- 2002-06-14 DK DK02751246T patent/DK1409672T3/da active
-
2003
- 2003-12-12 US US10/735,512 patent/US7417033B2/en not_active Expired - Lifetime
-
2007
- 2007-10-31 US US11/931,844 patent/US7855184B2/en not_active Expired - Fee Related
-
2008
- 2008-03-18 US US12/050,586 patent/US8828959B2/en not_active Expired - Fee Related
-
2009
- 2009-10-07 CY CY20091101035T patent/CY1109464T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE435911T1 (de) | 2009-07-15 |
| WO2002103014A2 (fr) | 2002-12-27 |
| DK1409672T3 (da) | 2009-11-09 |
| EP2166095A2 (fr) | 2010-03-24 |
| EP1409672A2 (fr) | 2004-04-21 |
| US7855184B2 (en) | 2010-12-21 |
| FR2826010B1 (fr) | 2005-02-25 |
| EP1409672B1 (fr) | 2009-07-08 |
| FR2826010A1 (fr) | 2002-12-20 |
| US20090082292A1 (en) | 2009-03-26 |
| WO2002103014A3 (fr) | 2004-02-26 |
| AU2002345669B9 (en) | 2006-06-29 |
| DE60232883D1 (de) | 2009-08-20 |
| ES2331835T3 (es) | 2010-01-18 |
| US20080293658A1 (en) | 2008-11-27 |
| JP2004538272A (ja) | 2004-12-24 |
| CY1109464T1 (el) | 2014-08-13 |
| US20040162257A1 (en) | 2004-08-19 |
| US7417033B2 (en) | 2008-08-26 |
| JP4153421B2 (ja) | 2008-09-24 |
| CA2451874A1 (fr) | 2002-12-27 |
| EP2166095A3 (fr) | 2012-01-04 |
| AU2002345669B2 (en) | 2006-02-02 |
| US8828959B2 (en) | 2014-09-09 |
| CA2451874C (fr) | 2013-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109464T1 (el) | Αντισυνθετικα ολιγονουκλεοτιδια ικανα να αναστειλουν την δημιουργια τριχοειδων σωληνων | |
| Lee et al. | Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo | |
| Gillitzer et al. | Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ | |
| US5650316A (en) | Uses of triplex forming oligonucleotides for the treatment of human diseases | |
| George et al. | siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats | |
| Ashcroft et al. | The effects of ageing on cutaneous wound healing in mammals | |
| Overall et al. | Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression | |
| EP0716610B1 (en) | Human bone morphogenetic proteins for use in neural regeneration | |
| Franchi et al. | Expression of transforming growth factor β isoforms in osteosarcoma variants: association of tgfβ1 with high‐grade osteosarcomas | |
| Weinreb et al. | Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost | |
| ES2527131T3 (es) | Polinucleótidos anticonexina como composiciones para la curación alterada de heridas | |
| Désiré et al. | Endogenous and Exogenous Fibroblast Growth Factor 2 Support Survival of Chick Retinal Neurons by Control of Neuronal Neuronal bcl‐xL and bcl‐2 Expression Through a Fibroblast Berowth Factor Receptor 1‐and Erk‐Dependent Pathway | |
| US9738892B2 (en) | Treatment of fibrotic conditions | |
| RU95104940A (ru) | Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения | |
| US20110130710A1 (en) | Treatment of abnormal or excessive scars | |
| BR112015031018B1 (pt) | Composição compreendendo um tetrapeptídeo para tratamento de condições da pele | |
| Xu et al. | Sodium tanshinone IIA sulfonate protects mice from ConA-induced hepatitis via inhibiting NF-κB and IFN-γ/STAT1 pathways | |
| Mahmoud et al. | Osteoblast-based therapy—a new approach for bone repair in osteoporosis: pre-clinical setting | |
| Bothwell | Neurotrophin function in skin | |
| MY134778A (en) | Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization | |
| US10758559B1 (en) | Targeting cathepsin K to facilitate wound healing | |
| Gilbert et al. | SPARC gene expression is reduced in early diabetes-related kidney growth | |
| Alsaegh et al. | Odontogenic epithelial proliferation is correlated with COX-2 expression in dentigerous cyst and ameloblastoma | |
| ES2188581T3 (es) | Modulacion por oligonucleotidos de la adherencia celular. | |
| Sahlberg et al. | Tenascin‐C in developing mouse teeth: expression of splice variants and stimulation by TGFβ and FGF |